No profile data available.
Sol-Gel Technologies Ltd. (SLGL) is a healthcare company in the skin treatment pharmaceuticals industry, based in Ness Ziona, Israel, with about 28 full-time employees.
It reported revenue of $19.39 million for fiscal year 2025, up 68.0% from fiscal year 2024, and net income of -$6.13 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $591,000, down 96.6% from a year before. United States was its largest region in fiscal year 2025, with 86% of revenue. Its market capitalization was $234.97 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally.
Sol-Gel Technologies reported $19.39 million in revenue for fiscal year 2025, up 68.0% from $11.54 million in fiscal year 2024. In Q2 2026 revenue was $591,000.
United States: 86% of revenue by region in fiscal year 2025, followed by Canada (9%).
$234.97 million as of October 9, 2026.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Avalo Therapeutics, Inc. (AVTX), Abeona Therapeutics Inc. (ABEO), Q32 Bio Inc. (QTTB), Journey Medical Corporation (DERM).